Skip to main content

Table 1 Baseline characteristics of patients after immune checkpoint inhibitor treatment

From: Association between the type of thyroid dysfunction induced by immune checkpoint inhibitors and prognosis in cancer patients

 

Thyroid irAE (N = 58)

No thyroid irAE (N = 127)

P value

Age (years) a

66.7 ± 11.1

64.1 ± 11.2

0.140

Male, n (%)

44 (75.9%)

91 (71.7%)

0.675

BMI (kg/m2)

23.2 ± 2.9

22.2 ± 4.0

0.060

T4 replacement before ICI treatment

4 (6.9%)

4 (3.1%)

0.440

Underlying malignancy, n (%)

  

0.238

 lung

40 (69.0%)

72 (56.7%)

 

 melanoma

3 (5.2%)

19 (15.0%)

 

 urothelial cancer

2 (3.4%)

5 (3.9%)

 

 breast

0 (0%)

1 (0.8%)

 

 colon

0 (0%)

1 (0.8%)

 

 esophagus

3 (5.2%)

0 (0.0%)

 

 HCC

1 (1.7%)

3 (2.4%)

 

 jejunum

0 (0%)

1 (0.8%)

 

 mesothelioma

1 (1.7%)

4 (3.1%)

 

 head and neck cancer

1 (1.7%)

8 (6.3%)

 

 ovary

0 (0%)

1 (0.8%)

 

 pancreas

1 (1.7%)

0 (0.0%)

 

 renal

2 (3.4%)

2 (1.6%)

 

 skin

0 (0%)

1 (0.8%)

 

 stomach

4 (6.9%)

8 (6.3%)

 

 thymoma

0 (0%)

1 (0.8%)

 

Immune check point inhibitor, n (%)

  

0.196

 pembrolizumab

37 (63.8%)

63 (49.6%)

 

 nivolumab

16 (27.6%)

50 (39.4%)

 

 atezolizumab

7 (8.6%)

14 (11.0%)

 

Death, n (%)

19 (32.8%)

64 (50.4%)

0.038

Treatment duration b (month)

8.1 ± 8.0

4.0 ± 6.8

 < 0.001

Period from initiation of ICI treatment to death (month)

14.4 ± 10.9

9.7 ± 10 .0

0.004

  1. irAE immune related Adverse Event, BMI Body Mass Index, HCC Hepatocellular Carcinoma, ICI Immune Check point Inhibitor
  2. aAge at ICI initiation
  3. bthe time from ICI treatment initiation date to last ICI treatment date